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The P2Y1 receptor promotes chloride secretion in epithelial cells, a process critical for regulation of extracellular ion and fluid
levels. Here we have examined the role of phosphorylation in agonist-induced internalization of P2Y1 receptors.
EXPERIMENTAL APPROACH
A high-affinity radiolabelled antagonist, MRS2500, was used to quantify cell surface-binding sites of P2Y1 receptors in
Madin-Darby canine kidney (MDCK) epithelial cells, following exposure to agonists. The regions in the carboxyl terminus
involved in both agonist-induced internalization of the receptor and its phosphorylation were identified by mutational
analysis.
KEY RESULTS
Endogenous and stably expressed recombinant P2Y1 receptors rapidly internalized with similar time courses in response to
agonist in MDCK cells, ensuring that the levels of recombinant receptor achieved by retroviral infection did not adversely
affect function of the internalization machinery. Four protein kinase C inhibitors of varying specificity did not affect
internalization of recombinant receptors. Agonist-promoted internalization of a series of truncated P2Y1 receptors identified a
region between residues 349 and 359 in the carboxyl terminus as critical for regulation. Two amino acids within this region,
Ser352 and Ser354, were shown to be both necessary and sufficient for agonist-promoted receptor phosphorylation and
internalization.
CONCLUSIONS AND IMPLICATIONS
Our results firmly establish Ser352 and Ser354 in the carboxyl terminus of P2Y1 receptors as critical residues for agonist-
induced receptor internalization in MDCK cells. As the mechanism mediating this regulation requires phosphorylation of these
key residues, the relevant receptor-regulated protein kinase can now be identified.
Abbreviations
2MeSADP, 2-methyl thioadenosine 5′-diphosphate; GPCR, G protein-coupled receptor; HEK293, human embryonic
kidney 293; MDC, monodansylcadaverine; MDCK, Madin-Darby canine kidney; MRS2179, 2′-deoxy-N6-
methyladenosine 3′,5′-bisphosphate; MRS2279, 2-chloro-N6-methyl-(N)-methanocarba-2′-deoxyadenosine-3′,5′-
bisphosphate; MRS2500, 2-iodo-N6-methyl-(N)-methanocarba-2-deoxyadenosine-3,5-bisphosphate; PKC, protein kinase
C; PMA, phorbol 12-myristate 13-acetate
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Introduction
A clear understanding of the mechanisms governing
agonist-promoted regulation of G protein-coupled receptors
(GPCRs) is critical for understanding the actions of current
and potential therapeutic agents. Cells have evolved a
number of ways to regulate agonist-promoted signalling of
these receptors, including a system of receptor desensitiza-
tion and internalization, which prevents further coupling to
and activation of G proteins. The current model for GPCR
desensitization and internalization, involving phosphoryla-
tion by GPCR kinases, arrestin binding and internalization
into clathrin-coated pits, is largely based on studies of the
b2-adrenoceptor. However, many other GPCRs desensitize
and internalize by other mechanisms (Waugh et al., 1999;
Bhattacharyya et al., 2002; Paing et al., 2002; Pierce et al.,
2002).
The P2Y family of GPCRs is activated by extracellular
adenine and uridine nucleoside di- and triphosphates and
nucleotide sugars. The eight recognized mammalian P2Y
receptors are subclassified based on sequence homology and
G protein coupling. P2Y1, P2Y2, P2Y4, P2Y6 and P2Y11 recep-
tors (receptor nomenclature follows Alexander et al., 2009)
are members of the P2Y1 subfamily of receptors that
promote inositol lipid signalling through Gaq-dependent
activation of phospholipase C-b. P2Y12, P2Y13 and P2Y14
receptors are members of the P2Y12 subfamily of receptors
that couple to the Gi family of Ga subunits to inhibit
adenylyl cyclase activity (Costanzi et al., 2004; Abbracchio
et al., 2006).
The ADP-activated P2Y1 and P2Y12 receptors are
expressed in platelets and mediate ADP-promoted platelet
aggregation (Hechler et al., 1998; Jin et al., 1998; Jantzen
et al., 1999; Hollopeter et al., 2001). We showed recently
that the P2Y1 receptor in platelets desensitizes very
rapidly (t1/2 ~18 s) in response to the selective agonist
( N ) - methanocarba - 2 - methylthioadenosine - diphosphate
(MRS2365) (Bourdon et al., 2006). Others have reported
that the P2Y1 receptor is phosphorylated in an agonist-
dependent manner and undergoes rapid, reversible internal-
ization in human platelets and 1321N1 astrocytoma cells.
Both conventional and novel isoforms of protein kinase C
(PKC), but not GPCR kinases, have been implicated
(Baurand et al., 2000; Hardy et al., 2005; Mundell et al.,
2006).
We have described the synthesis and utility of two high-
affinity radioligands ([32P]MRS2500 and [125I]MRS2500) with
identical binding properties for quantification of P2Y1
receptor-binding sites in mammalian tissues (Houston et al.,
2006; Ohlmann et al., 2010). Here, we apply radiolabelled
MRS2500 as a probe in studies designed to determine the
molecular determinants of agonist-induced internalization
of the P2Y1 receptor. Agonist-promoted loss of surface-
binding sites of both endogenous and stably expressed
receptors was quantified directly, and Ser352 and Ser354 in
the carboxyl terminus were identified as important sites for
both agonist-promoted phosphorylation and consequent
internalization of P2Y1 receptors. A preliminary account of
these data has been published elsewhere (Morris-Glast et al.,
2008).
Methods
Construction of mutant P2Y1 receptor cDNAs
The human P2Y1 receptor was cloned into the pLXSN retro-
viral expression vector with an amino-terminal HA-epitope
tag (YPYDVPDYA) following the initiating methionine
residue as described by Wolff et al. (2005). Unpublished
studies have demonstrated that incorporation of an amino-
terminal HA-epitope tag does not interfere with P2Y1 receptor
function. Truncation mutants were constructed by PCR
amplification using Pfu polymerase (Stratagene, La Jolla, CA,
USA) with a 5′ primer containing an EcoRI restriction site and
3′ primers containing a stop codon following Thr339 (P2Y1-
339Z), Asn349 (P2Y1-349Z), Asn359 (P2Y1-359Z) or Gly369
(P2Y1-369Z) and an XhoI restriction site to facilitate cloning
into similarly digested pLXSN.
The P2Y1-340/0P mutant receptor was constructed using
5′ and 3′ primers up to 60 bases in length in which all Ser and
Thr codons were mutated to Ala. The sense and antisense
primers contained XhoI and BamHI restriction sites, respec-
tively, at their 3′ ends. The primers, which overlapped by 18
bases, were annealed, filled-in with the Klenow fragment of
DNA polymerase, and then digested and ligated into the
P2Y1-339Z truncation mutant containing a silent mutation
that incorporated a XhoI site at codons 336–338. Mutation of
individual residues S343A, S346A, S352A, S354A and T354A,
the double residue mutants S352A/S354A and S343A/S346A,
and the triple residue mutant S352A/S354A/T358A were con-
structed using the Stratagene QuikChange Mutagenesis Kit
(Stratagene) with HA-P2Y1 in pLXSN as the template and
reverse complementary primers between 30 and 45 bases in
length containing alanine codon substitutions at the indi-
cated sites. Constructs were confirmed by DNA sequencing at
the UNC DNA Sequencing facility and purified using a
Purelink DNA purification kit (Invitrogen, Carlsbad, CA,
USA).
Cell culture and expression of
receptor constructs
Madin-Darby canine kidney (MDCK) epithelial cells were
maintained in 50/50 Dulbecco’s modified Eagle medium
(DMEM)/F12 medium (Invitrogen) supplemented with 5%
fetal bovine serum (Sigma, St. Louis, MO, USA). PA317 retro-
viral packaging cells were maintained in DMEM supple-
mented with 10% fetal bovine serum. Recombinant receptor
constructs were stably expressed in MDCK cells by retroviral
infection of target cells using the method of Comstock et al.
(1997) as described previously (Qi et al., 2001). Virally
infected cells were selected in medium containing 1 mg·mL-1
G418 antibiotic (Invitrogen). After approximately 7 days in
culture, the concentration of G418 was reduced to
0.2 mg·mL-1, and cells were cultured as above and used for
experiments.
Confocal microscopy of P2Y1 receptors
in MDCK cells
MDCK-P2Y1 cells expressing the HA-P2Y1 receptor were
plated on glass cover slips at 20–30% confluence and allowed
to grow for 24 h. The cells were cooled to 4°C, labelled with
mouse HA.11 antibody (Covance, Princeton, NJ, USA) and
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washed to remove excess antibody. The temperature was then
increased to 37°C and the cells were treated with either
phosphate-buffered saline (PBS) or 100 mM ADP for 30 min.
The cells were then fixed with 4% paraformaldehyde, perme-
abilized with ice-cold MeOH for 30 s, and then incubated
with AlexaFluor 488 goat anti-mouse antibody (Invitrogen/
Molecular Probes, Eugene, OR, USA). Cells were examined by
confocal microscopy on an Olympus Fluoview 300 laser scan-
ning confocal imaging system (Melville, NY, USA) configured
with an IX70 fluorescence microscope fitted with a PlanApo
60X oil objective. Quantification of confocal images was
accomplished with MetaMorph software as described (Wolff
et al., 2010).
Intact cell binding assays with
radiolabelled MRS2500
MRS2500 is a selective high affinity antagonist of the P2Y1
receptor (Kim et al., 2003), and we recently developed 32P-
(Houston et al., 2006) and 125I- (Ohlmann et al., 2010) labelled
forms of this molecule for quantification of the P2Y1 receptor
in radioligand binding assays. The binding properties of these
two radioligands are identical; therefore, [32P]MRS2500
(6000 Ci·mmol-1) and [125I]MRS2500 (2200 Ci·mmol-1) have
been used interchangeably in the current study, and to avoid
confusion, we do not usually designate whether individual
binding assays were carried out with the 32P- or 125I-labelled
radioligand. [32P]MRS2500 (Houston et al., 2006) and
[125I]MRS2500 (Ohlmann et al., 2010) were prepared as previ-
ously described. Intact cell binding assays were carried out
with wild-type MDCK cells plated in 12-well plates. Intact cell
binding assays with the various MDCK cell lines generated
after infection with pLXSN vectors for wild-type or mutant
P2Y1 receptors were carried out in 24-well plates, except
when directly comparing wild-type and recombinant recep-
tor levels, in which case 12-well plates were used. Assays were
carried out approximately 24 h after plating, when cell den-
sities were approximately 80–90% of confluence. The
medium was replaced with 1 mL of assay buffer (DMEM/F12
medium supplemented with 20 mM HEPES, pH 7.4), and the
culture plates were placed in a 37°C water bath for 15 min
prior to experiments. Receptor internalization was initiated
by addition of maximally effective concentrations of agonist
[usually 10 mM 2-methyl thioadenosine 5′-diphosphate
(2MeSADP) or 100 mM ADP], and incubations were termi-
nated by placing the culture plates on an ice-water slurry and
adding 8 mL of ice-cold wash buffer (1% BSA in PBS, pH 7.4).
Cells were washed two additional times with 8 mL of ice-cold
buffer. Intact cell binding assays were carried out by adding
0.1–0.5 nM of radiolabelled MRS2500 in 200 mL (24-well
plates) or 500 mL (12-well plates) of ice-cold assay buffer.
Non-specific binding was determined for each condition by
including 100 mM MRS2179 (Tocris-Cookson, Ellisville, MO,
USA). Steady-state binding is attained under these assay con-
ditions within 10 min, and therefore control and agonist-
preincubated cells were incubated with radiolabelled
MRS2500 for 10 min prior to removal of the medium and
addition and rapid aspiration of 8 mL of ice-cold wash buffer.
Cells were removed from the cell surface by addition of a
solution of 1% SDS in PBS, and radioactivity was quantified in
either a scintillation or gamma counter.
Experiments quantifying the reappearance of P2Y1 recep-
tors at the cell surface following incubation with ADP for
various times were carried out as described above but with
modifications. Briefly, cells were incubated with ADP for up
to 60 min with 100 mM ADP to initiate internalization. At the
end of the incubation, 0.1 U of potato apyrase (Sigma-
Aldrich, St. Louis, MO, USA) was added directly to the cell
medium to hydrolyse ADP (this amount of apyrase is enough
to completely hydrolyse 100 mM ADP to AMP within 1 min).
The cells were incubated for a further 30 or 60 min, and cell
surface P2Y1 receptors were quantified as described above.
Phosphorylation of HA-P2Y1 receptors
MDCK cells were seeded at a density of 2.5 ¥ 106 cells per
10 cm dish. After 48 h, cells were incubated first in
phosphate-free DMEM for 1 h at 37°C and then with 1 mCi
[32P]-orthophosphate for 3 h at 37°C. The cells were chal-
lenged with either buffer or 100 mM ADP for 5 min and
immediately placed on ice. Cells were lysed in RIPA buffer
(25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 1%
Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS) supple-
mented with protease and phosphatase inhibitors. Receptor
protein was immunoprecipitated with anti-HA.11 mono-
clonal antibody and Protein A/G beads, and then combined
with SDS gel loading buffer. A portion (80%) of the sample
was subjected to SDS-PAGE on a 10% gel, and incorporation
of 32P into the receptor was detected by exposing the fixed
and dried gel to X-OMAT film for 6–18 h at -80°C. The
remaining 20% of the sample was analysed by electrophoresis
on a 10% gel and receptor protein was detected by Western
blotting following transfer of proteins from the gel to a PVDF
support.
Data analysis
Data are presented as the mean  SEM from a data set from
a typical experiment repeated at least three times with similar
results, except for the experiments quantifying the reappear-
ance of P2Y, receptors at the cell surface, which were repeated
twice. Data were analysed using GraphPad Prism (GraphPad
Software, San Diego, CA, USA).
Results
Our laboratory and others have utilized MDCK cells as a
model system to study the membrane targeting and cell sig-
nalling properties of P2Y receptors. These cells endogenously
express low levels of the P2Y1 receptor (Wolff et al., 2005), and
therefore provide a system in which agonist-induced traffick-
ing of recombinant wild-type and mutant receptors can be
compared to P2Y1 receptors constitutively expressed in a
native environment.
MRS2500 is a selective, high-affinity P2Y1 receptor antago-
nist (Kim et al., 2003) that we recently labelled with 32P
(Houston et al., 2006) or 125I (Ohlmann et al., 2010) for appli-
cation as a radioligand for quantification of P2Y1 receptors in
a variety of mammalian cells and tissues. In this study, we
have utilized labelled MRS2500 to investigate agonist-
promoted trafficking of the P2Y1 receptor in MDCK cells. As
illustrated in Table 1A, the level of specific MRS2500 binding
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observed with intact wild-type MDCK cells was approxi-
mately eightfold less than in MDCK cells in which the P2Y1
receptor was overexpressed by retroviral infection (MDCK-
P2Y1 cells). The P2Y1 receptor antagonist, MRS2179, and the
P2Y1 receptor agonist, 2MeSADP, inhibited MRS2500 binding
to both wild-type or MDCK-P2Y1 cells with potencies similar
to those we previously reported for a variety of P2Y1 receptor-
expressing tissues (data not shown). Given the high hydro-
philicity of this bisphosphate radioligand, we expect that
essentially all MRS2500 binding detected in these assays is
from proteins on the cell surface.
Agonist-promoted changes in MRS2500-binding sites
were quantified in intact cell-binding assays with wild-type
(Figure 1A) and P2Y1 receptor-overexpressing (Figure 1B)
MDCK cells. Cells were incubated for various times at 37°C
with 10 mM 2MeSADP, washed with ice-cold buffer to remove
agonist, and incubated with radiolabelled MRS2500 on
ice under conditions in which steady-state binding was
obtained. Incubation with 2MeSADP caused a rapid decrease
(t1/2 ~8 min) in MRS2500-binding sites, and a similar time
course and extent of receptor loss was observed with wild-
type and recombinant receptors. No decrease in MRS2500-
binding sites occurred in cells preincubated with agonist
on ice instead of 37°C (data not shown). The potency of
2MeSADP (EC50 = 46 nM) for promoting loss of MRS2500-
binding sites (data not shown) was similar to the potency of
this agonist (EC50 = 13 nM) for activation of the P2Y1 receptor
(Schachter et al., 1996) and to its Ki (50 nM) determined in
radioligand-binding experiments (Houston et al., 2006). As
illustrated in Figure 1C, P2Y1 receptors were predominantly
localized at the plasma membrane in MDCK cells (98% by
image quantification) stably expressing HA-tagged P2Y1
receptors. However, a 30 min incubation with 100 mM ADP
resulted in the marked redistribution of receptors (47% by
image quantification) to intracellular vesicles.
The reversibility of the agonist-induced loss of MRS2500-
binding sites also was examined (Figure 2). MDCK-P2Y1 cells
were preincubated with either vehicle (0 min) or 100 mM ADP
for various times prior to addition of potato apyrase, a soluble
nucleotidase that rapidly converts ADP to AMP under the
conditions of these assays. Preincubation of cells with agonist
for 60 min resulted in an ~80% decrease in MRS2500-binding
sites, and addition of apyrase resulted in recovery of approxi-
mately one-half of these receptors over the ensuing 60 min.
Importantly, apyrase did not affect the number of MRS2500-
binding sites when added to cells in the absence of agonist
pretreatment, and the extent of recovery of binding sites was
dependent on the time of preincubation with agonist. Thus,
binding recovered to essentially control levels after addition
of apyrase to cells pretreated for only 5 min with ADP, but
this clearly was not the case with longer periods of preincu-
bation with agonist.
Taken together these results are consistent with the
conclusion that radiolabelled MRS2500 detects cell surface
P2Y1 receptors, and that both native and overexpressed P2Y1
receptors undergo agonist-promoted internalization to an
intracellular compartment of MDCK cells. Importantly,
agonist-promoted trafficking of recombinant P2Y1 receptors
is similar to that of endogenous P2Y1 receptors, which vali-
dates this system for the evaluation of receptor mutants. The
fact that the agonist-induced loss of MRS2500-binding sites
observed after 5 min of incubation with agonist is reversible
upon removal of ADP from the medium also is consistent
with a model in which agonists promote trafficking of P2Y1
receptors to an intracellular compartment that is inaccessible
to radioligand. Upon removal of agonist, these receptors are
trafficked back to the cell surface.
Clathrin-mediated endocytosis has been suggested to
occur for many GPCRs including P2Y1 receptors in human
platelets (Baurand et al., 2005; Mundell et al., 2008). To
determine if internalization of the P2Y1 receptor in MDCK
cells occurs through a clathrin-dependent mechanism, we
examined the effects of monodansylcadaverine (MDC) and
dynasore, two drugs that inhibit clathrin-mediated processes
(Schutze et al., 1999; Paing et al., 2002; Kirchhausen et al.,
2008). The presence of either compound decreased agonist-
induced loss of cell surface receptors by 30–40% (Figure 3).
Incubation with a high concentration of sucrose, which also
inhibits the formation of clathrin-coated pits (Heuser and
Anderson, 1989), completely prevented agonist induced loss
of MRS2500-binding sites in MDCK-P2Y1 cells (data not
shown). These data are consistent with the idea that clathrin-
coated pit formation contributes to internalization of P2Y1
receptors in MDCK cells.
Agonist-promoted internalization of GPCR predictably
occurs as a consequence of phosphorylation of activated
receptors, and conventional and novel isoforms of PKC were
reported to promote agonist-dependent phosphorylation and
internalization of the P2Y1 receptor in human platelets and
1321N1 astrocytoma cells (Mundell et al., 2006). To deter-
mine if PKC isozymes are involved in P2Y1 receptor internal-
ization in MDCK cells, we examined the capacities of four
different PKC inhibitors to block agonist-induced internaliza-
tion. MDCK-P2Y1 cells were preincubated for 10 min with
vehicle or with 1 mM GF109203X (a pan-PKC inhibitor),
10 mM Gö6983 (inhibits PKC-a, -b, -g, -d and -z isoforms),
Table 1













MDCK 565 300 0.056
MDCK-P2Y1 2455 390 0.43
B
MDCK-P2Y1 4325 1390 0.61




Binding reactions were carried out in a 12-well culture dish (~0.9
¥ 106 cells) with 0.1 nM [125I]MRS2500 [a concentration well
below saturating levels (Ohlmann et al., 2010)]. Non-specific
binding was determined in the presence of 100 mM 2MeSADP.
The data are representative of results obtained in many experi-
ments with each of the cell lines studied. MDCK, Madin-Darby
canine kidney.
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10 mM Ro31-8245 (inhibits PKC-a, -bI, -bII, -g and -e) or 10 mM
rottlerin (selective for PKC-d), and the incubation then was
continued in the presence or absence of 100 mM ADP for an
additional 30 min. ADP promoted an approximately 65%
decrease in MRS2500-binding sites on intact cells under these
conditions, and this level of agonist-induced internalization
was not altered by any of the PKC inhibitors (Figure 4A).
In contrast, three of the four inhibitors markedly inhibited
the capacity of phorbol 12-myristate 13-acetate (PMA) to
promote phosphorylation of ERK1/2, indicating that a con-
siderable inhibition of PKC was achieved under the condi-
tions of this experiment (Figure 4B). These data suggest that
PKC does not play a major role in agonist-induced internal-
ization of the P2Y1 receptor in MDCK cells.
We hypothesized that agonist-induced phosphorylation
of a residue(s) in the carboxyl terminus plays a key role in
agonist-promoted internalization of the P2Y1 receptor, and a
potential role was investigated for the nine Ser and Thr resi-
dues in this region. A series of mutants was constructed that
progressively truncated the carboxyl terminus (Figure 5), and
these P2Y1 receptor mutants were stably expressed in MDCK
cells by retroviral infection. The amount of specific MRS2500
binding determined for each cell line was similar to that
observed for MDCK cells stably expressing the wild-type P2Y1
receptor (data not shown), and the EC50 values of 2MeSADP
for stimulation of inositol lipid signalling also were similar
for each of these truncation mutants (data not shown).
Intact cell MRS2500-binding assays were utilized to deter-
mine whether these truncation mutants differed in their
capacity to undergo agonist-promoted internalization during
a 30 min incubation with 30 mM 2MeSADP (Figure 6A). P2Y1-
369Z retains all Ser and Thr residues but lacks the Class I
PDZ-binding motif, Asp-Thr-Ser-Leu (-DTSL), at the extreme
C-terminus. The Na+/H+ exchanger regulatory protein,
NHERF, binds to this region and was proposed to act as a
scaffold for the receptor and its downstream effector, phos-
pholipase C-b1 (Fam et al., 2005). PDZ ligands in GPCRs also
have been suggested to play a role in surface retention time
and targeting to subsets of clathrin-coated pits (Puthenveedu
and von Zastrow, 2006). However, the degree of agonist-
Figure 1
Agonist-promoted loss of radiolabelled MRS2500 surface-binding sites in Madin-Darby canine kidney (MDCK) cells. MDCK cells expressing
endogenous (A) or recombinant (B) P2Y1 receptors were incubated with 10 mM 2MeSADP for the indicated times. Cells were chilled to 4°C,
washed thoroughly and surface-binding sites were quantified with MRS2500. All values are normalized to the total amount of MRS2500 binding
in the absence of agonist treatment. Data shown are means of triplicate samples  SEM from a representative experiment (n = 3). (C)
Internalization of the HA-tagged P2Y1 receptor in MDCK-P2Y1 cells was determined by confocal microscopy. Cells were treated with buffer (left
panel) or 100 mM ADP (right panel) for 30 min before fixing and immunostaining. Quantitative image analysis revealed a surface : internalized
ratio of staining of 98:2 in the absence of agonist and 53:47 in the presence of agonist.
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promoted internalization of P2Y1-369Z was similar to that
observed with the wild-type receptor, and therefore, the PDZ-
binding motif is not directly involved in agonist-promoted
internalization of the P2Y1 receptor in MDCK cells
(Figure 6A). Truncation of an additional 10 residues
(P2Y1-359Z) also had no effect on 2MeSADP-induced inter-
nalization. In contrast, the extent of agonist-promoted inter-
nalization of P2Y1-349Z truncated receptor was markedly
reduced, and a similarly low level of internalization was
observed with a receptor missing 10 additional residues
(P2Y1-339Z). Thus, the region between residues 349 and 359
appears to be critical in the mechanism of agonist-promoted
internalization of the P2Y1 receptor.
Time courses of agonist-induced loss of MRS2500-binding
sites were generated for the wild-type receptor, the P2Y1-339Z
truncation mutant and a mutant lacking the last seven Ser
and Thr residues of C-terminus (P2Y1-340/0P, see Figure 5). As
shown in Figure 6B, agonist-promoted loss of surface
MRS2500-binding sites in the P2Y1-339Z receptor mutant
occurred with much slower kinetics and to a lesser extent
than that of the wild-type receptor. Lack of rapid, agonist-
promoted internalization of the truncated P2Y1-339Z recep-
tor was mimicked almost identically by the P2Y1-340/0P
receptor mutant, indicating a clear role for carboxyl terminal
Ser and Thr residues, and by inference, phosphorylation, in
agonist-promoted internalization.
Two Ser residues (S352 and S354) and one Thr residue
(T358) are located between amino acids 349 and 359 in the
region crucial for agonist-induced internalization of the P2Y1
receptor, and each of these residues was mutated individually
to Ala with the goal of identifying putative phosphorylation
sites involved in internalization. However, the degree of
2MeSADP-induced internalization of P2Y1 receptors harbour-
ing single mutations at residues Ser352, Ser354 or Thr358 was
only marginally decreased relative to that observed with wild-
type receptor (Figure 6C). As serine clusters in the carboxyl
terminus of several GPCRs, including the P2Y4 receptor, were
shown to be important for agonist-induced internalization
(Brinson and Harden, 2001; Oakley et al., 2001), we generated
a double mutant receptor, P2Y1-S352A/S354A, and measured
the rate and extent of agonist-induced loss of surface
MRS2500-binding sites. As observed with the P2Y1-339Z and
P2Y1-340/0P receptor mutants, the P2Y1-S352A/S354A double
mutant exhibited a marked impairment in agonist-induced
internalization (Figure 6D), and additional mutation of
T358A (i.e. a triple mutant) resulted in no further loss of
agonist-promoted internalization (data not shown). In con-
trast, mutation of the two upstream Ser residues, Ser343 and
Ser346, to Ala resulted in no impairment of agonist-promoted
internalization (data not shown), indicating that these resi-
dues are not involved in internalization. Both the P2Y1-339Z
and P2Y1-S352A/S354A mutant receptors were expressed at
similar levels as wild-type P2Y1 receptors (Table 1B). These
results illustrate that residues Ser352 and Ser354 are required
for agonist-promoted internalization of the P2Y1 receptor in
MDCK cells.
To assess directly whether Ser352 and Ser354 are subject
to agonist-promoted phosphorylation, we examined the
capacity of wild-type, P2Y1-340/0P and P2Y1-S352A/S354A
receptors to be phosphorylated in an agonist-dependent
manner. MDCK cells expressing HA-tagged receptors were
preincubated with [32P]phosphate to label the ATP pool, and
then incubated with 100 mM ADP for 5 min. ADP promoted a
marked incorporation (3.3-fold over basal) of 32P into wild-
type P2Y1 receptors (Figure 7). In contrast, no agonist-
Figure 2
Reversibility of agonist-promoted loss of cell surface P2Y1 receptors.
Madin-Darby canine kidney cells expressing recombinant P2Y1
receptors were incubated with buffer (0 min) or 100 mM ADP for 5,
15, 30, 60, 90 or 120 min. Potato apyrase (0.1 U) then was added to
rapidly hydrolyse the ADP (including buffer-treated cells), the cells
were allowed to recover for 30 or 60 min, and the levels of cell
surface P2Y1 receptor-binding sites were quantified by MRS2500
binding. All values were normalized to the total amount of MRS2500
bound in the absence of agonist treatment. Data shown are means of
triplicate samples  SEM from a representative experiment (n = 2).
Figure 3
Internalization of P2Y1 receptors in Madin-Darby canine kidney
(MDCK) cells is dynamin- and clathrin-dependent. MDCK cells stably
expressing recombinant P2Y1 receptors were incubated with 10 mM
2MeSADP for 30 min in the absence (Buffer) or presence of mon-
odansylcadaverine (MDC; an inhibitor of clathrin endocytosis) or
dynasore (an inhibitor of the dynamin GTPase). MRS2500-binding
sites were then quantified. All values are normalized to the total
amount of radiolabelled MRS2500 binding in the absence of agonist
treatment. Data shown are means of triplicate samples  SEM from
a representative experiment (n = 3). **P < 0.01.
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promoted incorporation of 32P occurred with the P2Y1-340/0P
or P2Y1-S352A/S354A receptors, which is consistent with
the marked decrease in agonist-promoted internalization
observed with these mutant receptors (Figure 6B,D). These
data indicate that agonist-induced phosphorylation occurs at
two residues, Ser352 and Ser354, and suggest that phospho-
rylation of these two residues is critical in the mechanism of
agonist-promoted internalization of the P2Y1 receptor.
Discussion and conclusions
In the studies presented here, we describe the use of a selec-
tive, high-affinity radioligand to examine agonist-induced
changes in cell surface P2Y1 receptors. Agonists promote the
loss of cell surface receptors in both wild-type MDCK cells
and in MDCK cells stably overexpressing P2Y1 receptors with
similar rates. Loss of surface receptors is promoted with a
concentration dependence for agonist that closely coincides
with that for P2Y1 receptor binding and activation, is inde-
pendent of PKC and is dependent on the formation of
clathrin-coated pits. Taken together, our data strongly suggest
that these changes occur as a consequence of an agonist-
dependent increase in the rate of internalization, but we do
not formally rule out the occurrence of additional changes in
other processes of receptor trafficking, for example recycling.
Two Ser residues in the carboxyl terminus of the P2Y1 recep-
tor, Ser352 and Ser354, were shown to be critical for agonist-
promoted internalization. Moreover, these two Ser residues
are phosphorylated in an agonist-dependent manner, and
their mutation results in marked inhibition of both agonist-
induced phosphorylation and internalization of the receptor.
Thus, our studies strongly suggest an obligatory role for
agonist-induced phosphorylation in the process of agonist-
dependent internalization of the P2Y1 receptor, and the two
key residues involved in this activity have been identified.
The development of the selective radioligands
[32P]MRS2500 and [125I]MRS2500 is the result of a series of
structure–activity relationships and molecular modelling
studies of the P2Y1 receptor that in collaboration with Jacob-
son and his colleagues have yielded a number of high-affinity
antagonists and radioligands, including MRS2500, a potent
antiplatelet agent in vivo, and [3H]MRS2279, the first non-
nucleotide antagonist radioligand for a P2Y receptor (Waldo
et al., 2002; Hechler et al., 2006). These compounds have
proved invaluable for studying the activity of P2Y1 receptors
in various physiological systems and mammalian cell lines.
The development of high-specific-radioactivity radioligands
of MRS2500 introduces important new methodology, as their
high-specific radioactivity (i.e. 6000 and 2200 Ci·mmol-1 for
[32P] and [125I] forms of MRS2500, respectively) provides the
sensitivity needed to quantify P2Y1 receptors in all tissues as
shown by detection of P2Y1 receptors in rat tissues at receptor
densities less than 10 fmol·mg-1 of protein, as well as in
human platelets (Houston et al., 2006; Ohlmann et al., 2010).
Therefore, these radioligands were applied to quantify
agonist-promoted internalization of endogenous P2Y1 recep-
tors of MDCK cells as well as the trafficking of recombinant
wild-type and mutant receptors. Observation of agonist-
Figure 4
Internalization of P2Y1 receptors in Madin-Darby canine kidney (MDCK) cells is independent of protein kinase C (PKC). MDCK cells stably
expressing recombinant P2Y1 receptors were preincubated for 10 min with the PKC inhibitors GF109203X (1 mM), Gö6983 (10 mM), Ro31-8245
(10 mM) or rottlerin (10 mM), following which either buffer or 100 mM ADP was added and the cells were further incubated for 30 min.
MRS2500-binding sites were then quantified. All values are normalized to the total amount of radiolabelled MRS2500 binding in the absence of
agonist treatment. Data shown are means of triplicate samples  SEM from a representative experiment (n = 3). (B) The capacity of the PKC
inhibitors to block phorbol 12-myristate 13-acetate (PMA)-promoted ERK phosphorylation in MDCK cells is shown. The inhibitors were used at
the same concentrations as in (A). Per cent inhibition of PMA-promoted ERK phosphorylation is shown for each inhibitor (n = 3).
Figure 5
P2Y1 mutant constructs expressed in Madin-Darby canine kidney
cells. Ser and Thr residues in the carboxyl tail of the wild-type
receptor are highlighted in red, and those residues mutated to
alanine are highlighted in green. Numbered residues indicate the last
residue before insertion of a stop codon in the truncation mutants
(arrows).
BJP A-D Qi et al.
1310 British Journal of Pharmacology (2011) 162 1304–1313
induced internalization of the endogenous receptor indicates
that MDCK cells express the native cell machinery for
agonist-induced trafficking of P2Y1 receptors. Moreover, the
similarity of the kinetics of internalization for the endog-
enous receptor versus the recombinant receptor suggests that
this system is appropriate for evaluation of the physiologi-
cally relevant behaviour of overexpressed mutant receptors.
P2Y1 receptors in platelets internalize rapidly (>1 min) in
response to agonist treatment and reside in the open canali-
cular system (Baurand et al., 2005). The kinetics of this
response were much more rapid than those reported here
and in other studies (Tulapurkar et al., 2004), suggesting that
platelets perhaps utilize a distinct mechanism of internaliza-
tion. However, these experiments depended on the use of
antibodies whose sensitivity in detecting functional P2Y1
receptor-binding sites is not clear. MRS2500 provides a
useful radioligand for quantification of active receptors on
the surface of platelets (Ohlmann et al., 2010), and future
experiments will compare the properties of agonist-induced
internalization of the platelet receptor with those described
here.
A role for PKC in P2Y1 receptor desensitization, phospho-
rylation and internalization has been reported for both plate-
lets and 1321N1 human astrocytoma cells. Thr339 in the
C-terminus of the P2Y1 receptor is located within a PKC
consensus motif and was required for desensitization (Fam
et al., 2003; Hardy et al., 2005; Mundell et al., 2006). Our data
using inhibitors of various PKC isoforms (Figure 4)
Figure 6
Ser and Thr residues in the carboxyl terminus of the P2Y1 receptor are required for agonist-promoted internalization. (A) Madin-Darby canine
kidney (MDCK) cells stably expressing the indicated P2Y1 receptor truncation mutants were incubated with 10 mM 2MeSADP for 0 or 30 min and
cell surface MRS2500-binding sites were quantified. (B) MDCK cells stably expressing P2Y1, P2Y1-340/0P or P2Y1-339Z receptors were incubated
with 10 mM 2MeSADP for the indicated times and surface MRS2500-binding sites were quantified. (C) MDCK cells stably expressing the indicated
P2Y1 receptor single point mutants were treated with 10 mM 2MeSADP for 0 or 30 min and cell surface MRS2500-binding sites were quantified.
(D) MDCK cells stably expressing P2Y1 or P2Y1-S352/354A receptors were incubated with 10 mM 2MeSADP for the indicated times and cell surface
MRS2500-binding sites were quantified. All values are normalized to the total amount of radiolabelled MRS2500 binding in the absence of agonist
treatment. Data shown are means of triplicate samples  SEM from a representative experiment (n = 3). *P < 0.05; **P < 0.01 relative to wild-type
receptor. In (C), none of the single point mutants were significantly different from one another. WT, wild type.
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suggests that PKC was not required for agonist-promoted
internalization of P2Y1 receptor in MDCK cells. Moreover, our
data indicated that Thr339 is neither phosphorylated in
response to agonist nor required for P2Y1 receptor internal-
ization (Figures 6 and 7) in MDCK cells. The reason(s) for the
differences between earlier results and those described here
are unclear, but may be a function of the cell line used, that
is, 1321N1 astrocytoma cells instead of MDCK cells. Direct
observation of agonist-promoted phosphorylation of the
P2Y1 receptor and the relative absence of both phosphoryla-
tion and internalization of receptors bearing mutations of
Ser352 and Ser354 strongly suggests that phosphorylation
plays a key role in agonist-promoted trafficking of the P2Y1
receptor. Identification of the involved protein kinase(s)
remains unclear, although our data suggest that PKC is not
involved. GPCR kinases and Ca2+/calmodulin-dependent
protein kinases remain obvious possibilities.
A study of P2Y1 receptor internalization in 1321N1 and
HEK293 cells was reported while the current manuscript was
in preparation (Reiner et al., 2009). Interestingly, Ser352 and
Thr358 were identified as crucial residues involved in agonist-
promoted phosphorylation and internalization of the P2Y1
receptor in these cells, which differs from our results identi-
fying Ser352 and Ser354 as the most important residues in
agonist-promoted internalization in MDCK cells. An expla-
nation for our differing conclusions, in addition to the
obvious difference in cell lines, is that phosphorylation of
Ser352 and either Ser354 or Thr358 may be sufficient to
promote internalization. We show here that the markedly
reduced rate of agonist-promoted internalization of the P2Y1-
S352A/S354A receptor is identical to that observed with both
the P2Y1-349Z truncated receptor and the P2Y1-S352A/S354A/
T358A triple mutant receptor, and that no agonist-promoted
phosphorylation occurs in the double mutant. These results
demonstrate that in MDCK cells, Ser352 and Ser354 are nec-
essary and sufficient to promote agonist-induced internaliza-
tion of P2Y1 receptors.
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